Literature DB >> 29340891

Mitomycin C 0.02 and 0.002% efficacy in preventing haze after photorefractive keratectomy.

L M Coelho1, R O Sieiro2.   

Abstract

PURPOSE: To compare MMC 0.002% efficacy in preventing haze after PRK in relation to MMC 0.02%. PATIENTS AND METHODS: We conducted a prospective study with patients with myopia or myopic astigmatism undergoing PRK in the same conditions. After PRK, MMC was applied for 30 s in a concentration of 0.02% on the right eye (group 1) and 0.002% on the left eye (group 2). Age, gender, spherical equivalent and haze intensity (1, 3, 6 and 12 months postoperatively) were assessed. Haze was quantified at biomicroscopy (0-4 +). P < 0.05 was considered statistical significant.
RESULTS: We evaluated 130 patients, 77 women and 53 men, with a mean age of 30.2 ± 9 years. The spherical equivalent was - 3.66 D in the group 1 and - 3.77 D in the group 2. In the 1st month after PRK, incidence of haze was 13.9% eyes in group 1 and 14.6% in group 2. In the 3rd month, incidence of haze was 50.0% eyes in group 1 and 48.5% in group 2 which presented with 3 +/4 + traces of haze. In the 12th month, incidence of haze was 7.7% eyes in group 1 and 5.4% in group 2. There was no correlation between haze and age (p = 0.279/0.333), gender (p = 0.345/0.367) or spherical equivalent (p = 0.100/0.054) in groups 1 and 2, respectively. There was no difference in haze between groups 1 and 2 (p = 0.56).
CONCLUSION: MMC 0.002% was effective in preventing haze after PRK. As MMC long-term safety has not been proved, we suggest its use in a lower concentration, in order to prevent potential complications.

Entities:  

Keywords:  Corneal haze; Mitomycin C; PRK complications; Photorefractive keratectomy; Refractive surgical procedures

Mesh:

Substances:

Year:  2018        PMID: 29340891     DOI: 10.1007/s10792-017-0817-7

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  4 in total

1.  Plasma rich in growth factors versus Mitomycin C in photorefractive keratectomy.

Authors:  Ronald M Sanchez-Avila; Edmar E Uribe-Badillo; Javier Fernández-Vega Sanz; Francisco Muruzabal; Nancy Jurado; Belén Alfonso-Bartolozzi; Jose F Alfonso; Begoña Baamonde; Eduardo Anitua; Jesus Merayo-Lloves
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

Review 2.  Preferred practice patterns for photorefractive keratectomy surgery.

Authors:  Rajesh Fogla; Gaurav Luthra; Aishwarya Chhabra; Krati Gupta; Ritika Dalal; Pooja Khamar
Journal:  Indian J Ophthalmol       Date:  2020-12       Impact factor: 1.848

Review 3.  Mitomycin C application after photorefractive keratectomy in high, moderate, or low myopia: Systematic review and meta-analysis.

Authors:  Yassamine Ouerdane; Mohamed Sayed Zaazouee; Moaiad Eldin Ahmed Mohamed; Mohammed Tarek Hasan; Mohamed Hamdy; Abdallah Magdy Ghoneim; Mohamed Ibrahim Gbreel; Ahmed Mohamed Ibrahim; Khaled Mohamed Ragab; Anas Zakarya Nourelden
Journal:  Indian J Ophthalmol       Date:  2021-12       Impact factor: 1.848

4.  A Prospective, Randomized, Double-Masked Controlled Clinical Trial of Postoperative Pain after Transepithelial Photorefractive Keratectomy (Trans-PRK).

Authors:  Zhongping Lv; Ke Ma
Journal:  J Healthc Eng       Date:  2022-04-21       Impact factor: 3.822

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.